Results 61 to 70 of about 1,448,905 (180)
Design and Synthesis
of Novel Amino-triazine Analogues
as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment
of Rheumatoid Arthritis
, 2018 Bruton’s
tyrosine kinase (BTK) is a promising drug target
for the treatment of multiple diseases, such as B-cell malignances,
asthma, and rheumatoid arthritis.Masaaki Sawa (5801243), Takao Kiyoi (5801234), Yuko Asamitsu (5801240), Takayuki Irie (2438509), Haruka Taniguchi (5801237), Tomoko Inoue (528192), Tokiko Asami (5801231), Takahiro Miyake (2419702), Wataru Kawahata (5801228) +8 morecore +2 more sourcesThe Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis
Allergy, EarlyView.ABSTRACT
Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...Peter K. Smith, Nicholas P. West, Stanley Du Preez, Hugh A. Sampson, Peter W. Hellings, David Price, Liam O'Mahony, Carina Venter, Cezmi A. Akdis, Gil Yosipovitch +9 morewiley +1 more sourceSAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma
British Journal of Haematology, EarlyView.Summary
The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad +25 morewiley +1 more sourceIbrutinib‐induced severe liver injury
Clinical Case Reports, 2017 Key Clinical Message Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known.Amara G. Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram +7 moredoaj +1 more sourceLenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups
British Journal of Haematology, EarlyView.Summary
Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb +45 morewiley +1 more sourceIbrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes
Stem Cell Reports, 2019 Summary: Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF).Sanam Shafaattalab, Eric Lin, Effimia Christidi, Haojun Huang, Yulia Nartiss, Analucia Garcia, Jeehon Lee, Stephanie Protze, Gordon Keller, Liam Brunham, Glen F. Tibbits, Zachary Laksman +11 moredoaj +1 more sourceIbrutinib and standard immunochemotherapy in younger, high‐risk patients with diffuse large B‐cell lymphoma: A phase II study of GLA
British Journal of Haematology, EarlyView.Summary
Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2. Evgenii Shumilov, Marita Ziepert, Birte Friedrichs, Susanne Ghandili, Kai Wille, Bertram Glass, Maike Nickelsen, Peter Borchmann, Andreas Viardot, Andrea Kerkhoff, Philipp Berning, Sebastian Böttcher, Stefan Wirths, Tobias Kewitz, Mathias Hänel, Judith Dierlamm, Andreas Rosenwald, Bettina Altmann, Georg Lenz, Norbert Schmitz +19 morewiley +1 more sourceDisruption of fyn SH3 domain interaction with a proline-rich motif in liver kinase B1 results in activation of AMP-activated protein kinase [PDF]
, 2013 Fyn-deficient mice display increased AMP-activated Protein Kinase (AMPK) activity as a result of Fyn-dependent regulation of Liver Kinase B1 (LKB1) in skeletal muscle.Bastie, Claire C., Yamada, Eijiro, Eijiro Yamada, Eijiro Yamada (187269), Claire C Bastie, Claire C. Bastie, Claire C. Bastie (187271), Bastie Claire C., Yamada Eijiro +8 morecore +1 more sourceDiscovery of
JNJ-64264681: A Potent and Selective
Covalent Inhibitor of Bruton’s Tyrosine Kinase
Bruton’s tyrosine kinase (BTK) is a Tec family
kinase that
plays an essential role in B-cell receptor (BCR) signaling as well
as Fcγ receptor signaling in leukocytes.Mark S. Tichenor (2468158), Charlotte Pooley Deckhut (10526589), Haopeng Rui (177936), Cynthia Milligan (14033119), Scott D. Bembenek (2245663), Weixue Wang (1307655), Ivo Cornelissen (14033116), Kay Ahn (1523929), Christos Xiouras (1493032), Michael Huber (274369), Kia Sepassi (2498989), Alec D. Lebsack (2222389), Kevin D. Kreutter (8580129), Kathryn Packman (93334), J. Kent Barbay (2540770), Jianmei Wei (2428387), Leon Chang (1464883), Ulrike Philippar (204902), Genesis M. Bacani (1455166), Richard Alexander (406596), Jiejun Wu (65346), Jennifer D. Venable (2658031), Heather E. Murrey (1266897), Sriram Balasubramanian (80245), Elizabeth Rex (10526592), John J. M. Wiener (2984025), Mark Seierstad (1464892), James P. Edwards (2428411), Kathleen W. Clancy (2235769), Gavin Hirst (5436224), Marcello Gaudiano (843532), Kevin J. Coe (156425), Navin L. Rao (6454055), Mariette Bekkers (14033113) +33 morecore +2 more sourcesProfound Sinoatrial Arrest Associated with Ibrutinib
Case Reports in Oncological Medicine, 2017 Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia.Kanupriya Mathur, Aditya Saini, Kenneth A. Ellenbogen, Richard K. Shepard +3 moredoaj +1 more source